Skip to Content
Merck
All Photos(1)

Key Documents

59357-U

Supelco

Discovery® Cyano HPLC Column

5 μm particle size, L × I.D. 25 cm × 4.6 mm

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
41115700
eCl@ss:
32110501
NACRES:
SB.52

material

stainless steel column

Quality Level

Agency

suitable for USP L10

product line

Discovery®

feature

endcapped

manufacturer/tradename

Discovery®

packaging

1 ea of

extent of labeling

4.5% Carbon loading

parameter

≤70 °C temp. range
400 bar pressure (5801 psi)

technique(s)

HPLC: suitable
LC/MS: suitable

L × I.D.

25 cm × 4.6 mm

surface area

200 m2/g

surface coverage

3.5 μmol/m2

impurities

<10 ppm metals

matrix

silica gel, high purity, spherical base material
fully porous particle

matrix active group

cyano phase

particle size

5 μm

pore size

180 Å

operating pH range

2-8

application(s)

food and beverages

separation technique

hydrophilic interaction (HILIC)
normal phase
reversed phase

Looking for similar products? Visit Product Comparison Guide

Features and Benefits

  • Low hydrophobicity for rapid elution of hydrophobic analytes
  • Excellent peak shape and retention of strongly basic analytes
  • Retention of polar analytes
  • Unique selectivity
  • Significantly less retention than C18 (typically requires lower % organic mobile phase)
  • Stable, low-bleed LC-MS separations
  • Compatible with highly aqueous organic phases

Legal Information

Discovery is a registered trademark of Merck KGaA, Darmstadt, Germany

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

E F Nemeth et al.
The Journal of pharmacology and experimental therapeutics, 299(1), 323-331 (2001-09-19)
Despite the discovery of many ions and molecules that activate the Ca2+ receptor, there are no known ligands that block this receptor. Reported here are the pharmacodynamic properties of a small molecule, NPS 2143, which acts as an antagonist at
S L Able et al.
British journal of pharmacology, 162(2), 405-414 (2010-09-16)
The P2X7 receptor is implicated in inflammation and pain and is therefore a potential target for therapeutic intervention. Here, the development of a native tissue radioligand binding, localization and ex vivo occupancy assay for centrally penetrant P2X7 receptor antagonists is
Thomas J Woltering et al.
Bioorganic & medicinal chemistry letters, 18(3), 1091-1095 (2007-12-22)
A series of 1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives was evaluated as non-competitive mGluR2/3 antagonists. Replacement of a cyano group by a five-membered heterocycle produced compounds inhibiting the binding of [(3)H]-LY354740 to rat mGluR2 with low nanomolar affinity and consistent functional effect at both
Fan Zhang et al.
European journal of medicinal chemistry, 46(7), 3149-3157 (2011-04-26)
A series of novel 2-amino-3-cyano-6-(1H-indol-3-yl)-4-phenylpyridine derivatives were synthesized and their cytotoxic activity against A549, H460, HT-29 and SMMC-7721 cell lines was evaluated in vitro. Among them, ten compounds (10, 11, 14, 16, 17, 26, 27, 29, 30 and 31) displayed
Graciela B Arhancet et al.
Journal of medicinal chemistry, 53(16), 5970-5978 (2010-08-03)
A new 1,4-dihydropyridine 5a, containing a cyano group at the C3 position, was recently reported to possess excellent mineralocorticoid receptor (MR) antagonist in vitro potency and no calcium channel-blocker (CCB) activity. In the present study, we report the structure-activity relationships

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service